Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
Top Page
Allarity Therapeutics
(NASDAQ:ALLR)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.84
▼(-26.14% Downside)
Action:DowngradedDate:02/04/26
The score is weighed down primarily by weak financial performance—no revenue, ongoing losses, and sustained negative free cash flow—despite modest leverage and currently positive equity. Technicals also detract due to a clear downtrend with negative momentum, while valuation is constrained by negative earnings and lack of dividend support.
Positive Factors
VA-funded Phase 2 trial enrollment
A VA-funded Phase 2 trial materially reduces near-term cash burden and accelerates clinical validation. Access to 11 VA sites improves patient recruitment and data quality, raising the structural probability of trial completion and future partner interest over the coming months.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow shows the company is consuming capital faster than it generates it. This structural cash burn creates recurring funding needs, elevates dilution risk, and constrains R&D pacing and program expansion unless offset by external capital or milestone revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
VA-funded Phase 2 trial enrollment
A VA-funded Phase 2 trial materially reduces near-term cash burden and accelerates clinical validation. Access to 11 VA sites improves patient recruitment and data quality, raising the structural probability of trial completion and future partner interest over the coming months.
Read all positive factors
Allarity Therapeutics (ALLR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.01M
Dividend YieldN/A
Average Volume (3M)146.33K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth99.82%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding16,080,980
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$99.78M
Allarity Therapeutics Business Overview & Revenue Model
Company Description
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenopa...
How the Company Makes Money
Allarity Therapeutics, Inc. generates revenue primarily through strategic partnerships and licensing agreements with other pharmaceutical companies. These collaborations often involve upfront fees, milestone payments, and royalties on future sales...
Allarity Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -15.09M | -24.23M | -11.28M | -17.30M | -25.77M | -6.01M |
| Net Income | -15.31M | -24.52M | -11.90M | -16.06M | -26.65M | -6.60M |
Balance Sheet | ||||||
| Total Assets | 20.80M | 22.65M | 11.86M | 14.54M | 49.63M | 33.40M |
| Cash, Cash Equivalents and Short-Term Investments | 16.89M | 19.53M | 166.00K | 2.03M | 19.91M | 298.00K |
| Total Debt | 1.39M | 1.35M | 1.30M | 3.73M | 1.09M | 2.67M |
| Total Liabilities | 8.79M | 10.84M | 14.61M | 12.65M | 30.85M | 8.96M |
| Stockholders Equity | 12.01M | 11.81M | -2.75M | 1.89M | 18.78M | 24.44M |
Cash Flow | ||||||
| Free Cash Flow | -15.08M | -17.65M | -12.74M | -16.84M | -15.05M | -7.25M |
| Operating Cash Flow | -14.78M | -17.35M | -12.74M | -16.82M | -15.05M | -7.25M |
| Investing Cash Flow | -298.00K | -298.00K | 0.00 | 791.00K | 1.00M | -3.00K |
| Financing Cash Flow | 15.12M | 36.79M | 10.99M | -1.31M | 33.82M | 6.03M |
Allarity Therapeutics Technical Analysis
Negative
1.14
Price Trends
1.07
Positive
1.11
Positive
1.18
Negative
Market Momentum
0.03
Positive
50.24
Neutral
19.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Negative. The current price of 1.14 is below the 20-day moving average (MA) of 1.14, above the 50-day MA of 1.07, and below the 200-day MA of 1.18, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 50.24 is Neutral, neither overbought nor oversold. The STOCH value of 19.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALLR.
Allarity Therapeutics Risk Analysis
Allarity Therapeutics disclosed 87 risk factors in its most recent earnings report. Allarity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allarity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $22.64M | -0.39 | -119.92% | ― | -22.41% | 78.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $45.25M | -0.97 | -84.39% | ― | ― | 15.32% | |
46 Neutral | $27.99M | -17.14 | 354.21% | ― | 13.56% | 52.92% | |
40 Underperform | $18.01M | -2.07 | -112.05% | ― | ― | 99.82% |
* Healthcare Sector Average
ALLR
Allarity Therapeutics
1.12
-0.02
-1.75%
LSTA
Lisata Therapeutics
5.01
2.58
106.17%
CRIS
Curis
0.70
-1.69
-70.71%
LGVN
Longeveron
0.97
-0.75
-43.43%
Allarity Therapeutics Corporate Events
Private Placements and Financing
Allarity Therapeutics Secures Flexible Equity Financing Facility
Neutral
Jan 29, 2026
On January 28, 2026, Allarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC, giving the company the right, but not the obligation, to sell up to $6 million of newly issued common shares, or a lower ...
Private Placements and Financing
Allarity Therapeutics Completes Additional Private Equity Financing
Neutral
Dec 23, 2025
On September 22, 2025, Allarity Therapeutics entered into a securities purchase agreement with an accredited investor for a private placement of 1,562,500 shares of common stock and/or pre-funded warrants, raising approximately $2.5 million in gro...
Executive/Board Changes
Allarity Therapeutics Appoints Jeffrey Ervin as Full-Time CFO
Neutral
Dec 8, 2025
On December 3, 2025, Allarity Therapeutics, Inc. transitioned Jeffrey S. Ervin from a part-time to a full-time Chief Financial Officer role under a new employment agreement. This agreement includes an annual base salary of $367,700, restricted sto...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.